In the future, genetically modifying HSCs with CRISPR-Cas9 to deliver NgR(310)ecto-Fc may improve the safety of the treatment and possibly offer a new therapeutic option for progressive MS patients. Here, RTN4R is linked to myeloid sarcoma.